We use a patient-centric approach to identify and develop transformative medicines for the treatment of severe rare diseases. Our lead product candidate, apraglutide, is a next generation, long-acting synthetic GLP-2 analog which we are developing as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome.
June 29, 2023
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
BOSTON & BASEL, Switzerland --(BUSINESS WIRE)--Jun. 29, 2023-- Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational
June 26, 2023
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals
BASEL, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, announced that today's extraordinary general meeting